IBPL is an integrated biopharmaceutical company with in house facility for development, manufacturing of bulk and finished formulation. The facility is GMP certified from Europe, South-Africa, GCC to name a few. With Peg GCSF, GCSF, EPO and IFN commercialized, business alliances in 78 countries and seven more biosimilar molecules under development (including Mabs and fusion proteins), IBPL is on the path to become Global Biopharmaceutical Company. Knowledge, Quality, Speed and innovative business models are driving force of IBPL. It is scouting for business partners for its Products. IBPL provides CRAMS and clinical trial services in biologics with its sister concerns.

Intas Biopharmaceuticals (IBPL) made a strategic entry into the biotechnology arena in 2001 via the establishment of Indus Biotherapeutics Ltd.; a dedicated biotech research company, in Ahmedabad INDIA.

Indus focuses on the development of recombinant protein-based biotherapeutics for human use. The focus is on developing commercial-scale technology in a timely and cost effective way. Our expertise lies in recombinant strain development, process and product development, development of analytical methods, bio-chemical immunological analysis, process validation and scale-up.

We would like to tie up with a company who has strong regulatory, manufacturing and marketing capabilities. We are open to consider early stage tie ups for some of our ealry stage development biosimilars.